{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Chicago&page=8&state=Illinois",
    "query": {
      "state": "Illinois",
      "city": "Chicago",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 17795,
    "total_pages": 1780,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Chicago&page=9&state=Illinois&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Chicago&page=7&state=Illinois&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T16:55:10.668Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00051467",
      "title": "A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "TNFerade",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "GenVec",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-02-23",
      "last_synced_at": "2026-11-02T16:55:10.668Z",
      "location_count": 25,
      "location_summary": "La Jolla, California • Los Angeles, California • Orange, California + 20 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00051467"
    },
    {
      "nct_id": "NCT00772200",
      "title": "Neuropsychological and Behavioral Testing in Younger Patients With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Childhood Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "Cognitive Assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Month and older"
      },
      "enrollment_count": 1200,
      "start_date": "2009-02-27",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-11-02T16:55:10.668Z",
      "location_count": 163,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 119 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00772200"
    },
    {
      "nct_id": "NCT00128492",
      "title": "Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "AZLI 75 mg two times a day (BID)/ three times a day (TID)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 274,
      "start_date": "2005-08",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2011-05-19",
      "last_synced_at": "2026-11-02T16:55:10.668Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00128492"
    },
    {
      "nct_id": "NCT07778836",
      "title": "A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Friedreich Ataxia",
        "Friedreich's Ataxia"
      ],
      "interventions": [
        {
          "name": "Nomlabofusp",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Larimar Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 150,
      "start_date": "2026-10-26",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-02T16:55:10.668Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • Chicago, Illinois • Eatontown, New Jersey + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Eatontown",
          "state": "New Jersey"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07778836"
    },
    {
      "nct_id": "NCT03783936",
      "title": "Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Adenocarcinoma",
        "Esophageal Adenocarcinoma",
        "Metastasis",
        "HER-2 Gene Amplification"
      ],
      "interventions": [
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "5 fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ashwin Somasundaram",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2019-01-24",
      "completion_date": "2022-08-30",
      "has_results": true,
      "last_update_posted_date": "2023-12-19",
      "last_synced_at": "2026-11-02T16:55:10.668Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03783936"
    },
    {
      "nct_id": "NCT01506544",
      "title": "Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Anemia"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Mercy Hospital Kansas City",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 39,
      "start_date": "2011-12",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2014-12-12",
      "last_synced_at": "2026-11-02T16:55:10.668Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • New York, New York + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01506544"
    },
    {
      "nct_id": "NCT03219164",
      "title": "Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization",
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "AZLI",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Months to 18 Years"
      },
      "enrollment_count": 149,
      "start_date": "2017-11-28",
      "completion_date": "2021-09-23",
      "has_results": true,
      "last_update_posted_date": "2022-06-14",
      "last_synced_at": "2026-11-02T16:55:10.668Z",
      "location_count": 12,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 8 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03219164"
    },
    {
      "nct_id": "NCT05041309",
      "title": "Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Solid and Hematological Malignancies",
        "Autoimmune Diseases"
      ],
      "interventions": [
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Brexucabtagene Autoleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Anitocabtagene autleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "KITE-753",
          "type": "BIOLOGICAL"
        },
        {
          "name": "KITE-197",
          "type": "BIOLOGICAL"
        },
        {
          "name": "KITE-363",
          "type": "BIOLOGICAL"
        },
        {
          "name": "INT2104",
          "type": "BIOLOGICAL"
        },
        {
          "name": "KITE-512",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SPRX001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SPRX002",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ARC-T Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1500,
      "start_date": "2021-12-15",
      "completion_date": "2040-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-11-02T16:55:10.668Z",
      "location_count": 49,
      "location_summary": "Gilbert, Arizona • Duarte, California • La Jolla, California + 38 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05041309"
    },
    {
      "nct_id": "NCT01034631",
      "title": "BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "BNC105P",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoosier Cancer Research Network",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 154,
      "start_date": "2010-01",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2022-07-11",
      "last_synced_at": "2026-11-02T16:55:10.668Z",
      "location_count": 94,
      "location_summary": "Muscle Shoals, Alabama • Hot Springs, Arkansas • Burbank, California + 83 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Corona",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01034631"
    },
    {
      "nct_id": "NCT05480657",
      "title": "Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Brittle Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "AT-1501 IV Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Isolated cadaveric islet cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eledon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-09-30",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2023-01-18",
      "last_synced_at": "2026-11-02T16:55:10.668Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05480657"
    }
  ]
}